{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:58:16Z","timestamp":1789534696081,"version":"build-2803163510"},"reference-count":48,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2017.00001","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T03:35:16Z","timestamp":1484710516000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Anti-IL17A in Axial Spondyloarthritis\u2014Where Are We At?"],"prefix":"10.3389","volume":"4","author":[{"given":"Peter P.","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20985","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo controlled trial (ASSERT)","volume":"52","author":"Van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double blind, placebo-controlled trial","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl 78","key":"B8","first-page":"S43","article-title":"Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease","volume":"31","author":"Baraliakos","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial","volume":"56","author":"Van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomized, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of a randomized, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker na\u00efve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty four week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","article-title":"Targeting the interleukin-23\/17 axis in axial spondyloarthritis","volume":"28","author":"Paine","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.molimm.2013.07.016","article-title":"Inflammatory pathways in spondyloarthritis","volume":"57","author":"Hreggvidsdottir","year":"2014","journal-title":"Mol Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat Genet"},{"key":"B19","first-page":"S515","article-title":"HLA-B27 misfolding activates the IL-23\/IL-17 axis via the unfolded protein response in transgenic rats: evidence for a novel mechanism of inflammation","volume":"54","author":"Colbert","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.33321","article-title":"Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondyloarthritis-prone HLA-B27-transgenic rats","volume":"64","author":"Glatigny","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3109\/s10165-009-0166-0","article-title":"Ankylosing enthesitis associated with upregulated IFN-gamma and IL-17 production in (BXSBxNZB) F(1) male mice: a new mouse model","volume":"19","author":"Abe","year":"2009","journal-title":"Mod Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+CD3+CD4-CD8-entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17 cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/keu382","article-title":"IL-17 producing CD4+ T Cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities","volume":"54","author":"Jansen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17 positive mast cells contribute to synovial inflammation in spondyloarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nature Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1517\/14712598.2016.1167183","article-title":"Secukinumab (AIN457) in the treatment of ankylosing spondylitis","volume":"16","author":"Braun","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 2","key":"B31","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 10","key":"B33","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis in anti-TNF na\u00efve patients and those previously exposed to anti-TNF therapy: 52 week results from 2 randomised, double blind, placebo-controlled phase 3 trials [abstract]","volume":"67","author":"Baeten","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomized, double-blind placebo controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"Suppl 2","key":"B35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/annrheumdis-2016-eular.3684","article-title":"No increased incidence of inflammatory bowel disease among secukinumab treated patients with moderate to severe psoriasis, psoriatic arthritis or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies [abstract]","volume":"75","author":"Schrieber","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"B36","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/annrheumdis-2016-eular.2306","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2 year results from a phase 3 trial with subcutaneous loading and maintenance dosing (MEASURE 2) [abstract]","volume":"75","author":"Marzo-Ortega","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"B37","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/annrheumdis-2016-eular.2308","article-title":"Secukinumab improves physical function and quality of life in patients with active ankylosing spondylitis: 2 year data from MEASURE 1, a phase 3 randomised trial [abstract]","volume":"75","author":"Emery","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","article-title":"Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study","volume":"75","author":"Baraliakos","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"B39","first-page":"10","article-title":"Effect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab [abstract]","volume":"67","author":"Baraliakos","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"B40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2016-eular.3177","article-title":"Effect of secukinumab, an interleukin-17A inhibitor, on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of the phase 3 study, MEASURE 1","volume":"75","author":"Braun","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"Van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"Van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23097","article-title":"Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with TNF inhibitors","author":"Maas","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/ken334","article-title":"Switching anti-TNF therapy in ankylosing spondylitis","volume":"47","author":"Pradeep","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"B46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/annrheumdis-2016-eular.3311","article-title":"No reactivation of dormant Mycobacterium tuberculosis in human in vitro granuloma model after anti-IL-17A treatment, in contrast to anti-TNF treatment [abstract]","volume":"75","author":"Kapoor","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28 week prospective, open-label, proof of concept study (TOPAS)","volume":"74","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"B48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2016-eular.1847","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase 2, 16 week randomized, placebo controlled, dose ranging study [abstract]","volume":"75","author":"Van der Heijde","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T15:39:56Z","timestamp":1749915596000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,18]]},"references-count":48,"URL":"https:\/\/doi.org\/10.3389\/fmed.2017.00001","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,18]]}}}